KRAS and non-small cell lung carcinoma: It has been reported that in NSCLC patients with KRAS gene mutation, anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death ligand 1 (anti-PD-L1) immunotherapy is more effective compared to the non-mutated KRAS group in terms of the ORR, PFS, and OS [51,71,74,75].